Bull&Bear | RAPT, Lightbridge, & Douglas Elliman Surge Amid Positive Developments; Bicara & Upexi Face Steep Declines

In the realm of bullish stocks, RAPT Therapeutics (RAPT) saw a significant surge of 43.34%. HC Wainwright & Co. has initiated coverage on RAPT Therapeutics with a buy rating, reflecting positive sentiment toward the company's prospects. This endorsement has been a key driver in the stock's substantial rise.

Lightbridge (LTBR) experienced a robust increase of 42.59%, marking three consecutive days of gains with a 51.85% rise over this period. This growth has been spurred by the United States government, under President Trump's direction, signing an executive order aimed at broadening nuclear power usage and accelerating reactor construction. Such political support has created a favorable environment for Lightbridge's stock performance.

Douglas Elliman (DOUG) saw its stock price climb 35.51%, continuing a two-day upward trend with an overall gain of 38.10%. The stock's rise follows a report indicating that the company received a merger proposal from Anywhere Real Estate, driving investor optimism and heightened activity in the company’s shares.

Merus (MRUS) surged by 32.55% after the company released promising interim data from its cancer trials. The positive trial results underscore the potential efficacy of Merus's cancer treatment, which has greatly bolstered investor confidence.

Nano Nuclear (NNE) increased by 30.07%, marking consecutive gains over two days and a total rise of 39.53%. This notable performance reflects investor interest and optimism surrounding the nuclear sector, though further details are awaited to fully understand the underlying drivers.

On the bearish front, Bicara Therapeutics (BCAX) dropped significantly by 40.80%. The decline came after Bicara Therapeutics experienced a setback when its cancer drug trial failed to meet survival benchmarks. This disappointing result has sparked investor concerns about the company’s future capabilities in research and development as well as its market outlook, leading to a steep drop in its stock price.

Gyre Therapeutics (GYRE) fell by 22.57%, coinciding with the pricing of a $20 million common stock offering. Previously reported, Gyre Therapeutics issued 2.22 million shares of common stock at $9 per share to raise funds for its F351 trial, focusing on liver fibrosis related to MASH. Despite positive trial data, the stock issuance negatively impacted GYRE’s market performance.

Upexi (UPXI) observed a decline of 21.70%. The drop followed Upexi’s announcement of its first-quarter 2025 financial results and an update on Solana's fiscal strategy. Investors reacted negatively to the financial disclosure, reflecting concerns about the company's strategic handling.

Deckers Outdoor (DECK) decreased by 19.86% after its first-quarter outlook failed to meet expectations. The company faces pressures from tariffs and slowed sales of its Hoka brand, which are key challenges influencing its current stock trajectory.